218153-06-1

Upstream product

• 124-63-0 methanesulfonyl chloride 
• 218153-08-3 (E/Z)-5-[[[3-(hydroxymethyl)-phenyl-3-pyridyl]methylene]aminooxy]pentanoic acid ethyl ester 
• 500-22-1 3-pyridinecarboxaldehyde 
• 124038-07-9 3-bromo-O-(tert-butyldiphenylsilyl)benzyl ether 

Downstream Products

• 218153-08-3 (E/Z)-5-[[[3-(hydroxymethyl)-phenyl-3-pyridyl]methylene]aminooxy]pentanoic acid ethyl ester 
• 462656-34-4 5-[1-(3-Chloromethyl-phenyl)-1-pyridin-3-yl-meth-(E)-ylideneaminooxy]-pentanoic acid ethyl ester 

Relevant academic research and scientific papers

Approach to dual-acting platelet activating factor (PAF) receptor antagonist/thromboxane synthase inhibitor (TxSI) based on the link of PAF antagonists and TxSIs

A series of compounds (22-36) which possess dual-acting PAF antagonist/TxSI have been generated by the approach of linking the known PAF antagonists and TxIs, such as Ridogrel (1).

Novel Agents Combining Platelet Activating Factor (PAF) Receptor Antagonist with Thromboxane Synthase Inhibitor (TxSI)

Compounds 1 or 2 which possess dual-acting PAF antagonist/TxSI in a previous paper were modified and evaluated for the dual-acting activity. It was found that several compounds were potent dual-acting PAF antagonist/TxSI in and ex vivo. 6-(2-Chlorophenyl)-3-[4-[(E/Z)-6-ethoxycarbonyl-1-(3-pyridyl)-1- hexenyl]phenylmethyl]-8,11-dimethyl-2,3,4,5-tetrahydro-8H-pyrido[4′, 3′: 4,5]thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine (12) is excellent orally dual-acting PAF antagonist/TxSI.